CN107510689A - A kind of pharmaceutical composition for treating depression and its application - Google Patents
A kind of pharmaceutical composition for treating depression and its application Download PDFInfo
- Publication number
- CN107510689A CN107510689A CN201610437198.9A CN201610437198A CN107510689A CN 107510689 A CN107510689 A CN 107510689A CN 201610437198 A CN201610437198 A CN 201610437198A CN 107510689 A CN107510689 A CN 107510689A
- Authority
- CN
- China
- Prior art keywords
- eugenol
- cinnaldehydrum
- group
- pharmaceutical composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a kind of pharmaceutical composition for treating depression, and described pharmaceutical composition includes eugenol and cinnaldehydrum, and weight ratio is (4 12):1.Eugenol and cinnaldehydrum compatible use of the present invention is higher than to the significant effect of depression is used alone eugenol or cinnaldehydrum, and can reduce medicine dosage.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition containing eugenol and cinnaldehydrum, further relates to said composition and is preparing treatment suppression
Application in the medicine of strongly fragrant disease, belongs to field of medicaments.
Background technology
Depression is also known as Depressive, also known as melancholia, melancholy sexual dysfunction, be one kind using depressive mood as main feature
The disturbance of emotion.It mainly includes:Major depressive disorder, dysthymic disorder, seasonal affective disorder.Their coexpress
For：Long lasting for depressive emotion, and this mood is significantly more than necessary limit, self-doubt, feels body energy
Obvious reduction, can not it is any activity in realize it is happy.This kind of obstacle can also cause the somatic function of patient to lack of proper care, and such as sleep
Dormancy disorder or anorexia.Depression is to seriously endanger common disease, the frequently-occurring disease of human physical and mental health.With the day of social competition
Increasingly acute, physiology that people bear, psychological pressure are increasing, and the incidence of disease of depression has continuous elevated trend.Defend in the world
Raw tissue recent statistics result shows global illness rate about 11%, and predicts that the year two thousand twenty depression will turn into the medical treatment of global second
Illness.
Drug therapy is the primary treatment measure of moderate above paralepsy.The antidepressants of a current clinically line are almost
All it is Western medicine, mainly (SSRI, represents agents fluoxetine, Paxil, sertraline including selective serotonin reuptake inhibitor
Woods, Fluvoxamine, Citalopram and escitalopram), serotonin and NRI (SNRI,
Represent medicine Venlafaxine and Duloxetine), norepinephrine and specific serotonin energy antidepressants (NaSSA, represent
Medicine Mirtazapine) etc..Western medicine depression works very fast, but with a large amount of side effects, such as nausea, diarrhoea, increased weight, secretes
Sweat, sex dysfunction and impatience etc., many patients influence the treatment of disease because of side effect is not resistant to, and also have many suffer from
Person can produce drug dependence.Therefore, all active demand is a kind of effectively in global range, and safe and suitable long-term use is anti-
Depressant drug.
Chinese medicine has the advantage that Western medicine can not be realized in terms of toxic side effect is reduced.Eugenol is that a kind of have strong fourth
Fragrance, aldehydes matter not soluble in water, it is mainly used in antibacterial, hypotensive, it can also be used to perfume fragrance and various cosmetics
In essence and fragrance for detergents formula, the allotment of flavoring essence can be also used for.Natural eugenol is present in various plants, such as
Cloves, cassia bark, bavin osmanthus, nutmeg, sweet basil, clore basil, lemon balm and dill etc..Cinnaldehydrum is a kind of aldehydes organic compound
Thing, thick liquid is sticked for yellow, is largely present in the plants such as Chinese cassia tree.The peat-reek of the bark (i.e. cassia bark) of Chinese cassia tree is exactly
From this compound.Cloves and Chinese cassia tree are all the conventional Chinese medicine of the traditional Chinese medical science, and the spices that people's daily life is conventional, for a long time
Clinical application and daily use prove that the two is safe and reliable.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating depression；
The second object of the present invention is in the application in the offer pharmaceutical composition in the medicine for preparing treatment depression.
The purpose of the present invention is achieved by the following technical solution：
A kind of pharmaceutical composition for treating depression, described pharmaceutical composition include eugenol and cinnaldehydrum.
Preferably, the eugenol, the weight ratio of cinnaldehydrum are (4-12):1.
It is further preferred that the weight ratio of the eugenol, cinnaldehydrum is (5.5-7.5):1.
It is further preferred that the weight ratio of the eugenol, cinnaldehydrum is (7-7.5):1 or (5.5-7):1.
Still more preferably, the eugenol, the weight ratio of cinnaldehydrum are 5.5:1、7:1 or 7.5:1.
Eugenol of the present invention, cinnaldehydrum can be purchased from the market, can also be from the plant comprising eugenol, cinnaldehydrum
In isolate and purify to obtain, can also be obtained by chemical synthesis or biological synthesis method, its structural formula is respectively：
The eugenol, the purity of cinnaldehydrum are more than 85%；Preferably, the eugenol, the purity of cinnaldehydrum exist
More than 90%；It is further preferred that the purity of the eugenol, cinnaldehydrum is more than 95%.
In some embodiments, described pharmaceutical composition divided by eugenol and cinnaldehydrum monomer component as raw material with
Outside, can also include eugenol extract/active component and extract/active component comprising cinnaldehydrum as raw material, institute
The content of eugenol, cinnaldehydrum in extract/active component is stated more than 85%；It is preferred that more than 90%.
Extract/the active component comprising eugenol is extracted and is refining to obtain using the medicinal material comprising eugenol as raw material
Arrive, the extracting method includes the routines such as soak extraction, ultrasonic extraction, seepage pressure effects, refluxing extraction, steam distillation extraction and carried
Object space method is taken, the process for purification includes extraction, crosses silica gel, macroreticular resin, gel resin, reversed-phase resin, ion exchange resin
Etc. column chromatography；The medicinal material comprising eugenol such as cloves, cassia bark, bavin osmanthus, nutmeg, sweet basil, clore basil, lemon balm are transplanted
Trailing plants etc..
Extract/the active component comprising cinnaldehydrum is extracted and is refining to obtain using the medicinal material comprising cinnaldehydrum as raw material
Arrive, the extracting method includes the routines such as soak extraction, ultrasonic extraction, seepage pressure effects, refluxing extraction, steam distillation extraction and carried
Object space method is taken, the process for purification includes extraction, crosses silica gel, macroreticular resin, gel resin, reversed-phase resin, ion exchange resin
Etc. column chromatography；Medicinal material comprising the cinnaldehydrum such as Chinese cassia tree.
Pharmaceutical composition of the present invention routinely can be prepared into clinical conventional peroral dosage form or external preparation by preparation process
Type, wherein, the peroral dosage form includes capsule, soft capsule, tablet, granule, pill, powder or oral liquid；It is described outer
Include patch, ointment, emulsifiable paste, spray etc. with formulation；Preferably capsule, tablet, granule；More preferably soft capsule.
To enable above-mentioned formulation to realize, it is necessary to add conventional formulation auxiliary material, including filler, disintegrant, lubricant, help
Suspension, adhesive, sweetener, flavouring, preservative, matrix etc..Filler includes：Starch, pregelatinized starch, lactose, sweet dew
Alcohol, chitin, microcrystalline cellulose, sucrose etc.；Disintegrant includes：Starch, pregelatinized starch, microcrystalline cellulose, CMS
Sodium, PVPP, low-substituted hydroxypropyl cellulose, Ac-Di-Sol etc.；Lubricant includes：Stearic acid
Magnesium, lauryl sodium sulfate, talcum powder, silica etc.；Suspending agent includes：Polyvinylpyrrolidone, microcrystalline cellulose, sugarcane
Sugar, agar, hydroxypropyl methyl cellulose etc.；Adhesive includes：Starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose
Deng；Sweetener includes：Saccharin sodium, aspartame, sucrose, honey element, enoxolone etc.；Flavouring includes：Sweetener and various
Essence；Preservative includes：Parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene be fixed,
Eucalyptus oil etc.；Matrix includes：PEG6000, PEG4000, insect wax etc..
The invention also discloses purposes of the described pharmaceutical composition in the medicine for preparing treatment depression.
Pharmacological research shows that the present invention has the composition of eugenol, cinnaldehydrum compatible use to depression good
Curative effect, its is evident in efficacy higher than eugenol or cinnaldehydrum is used alone, particularly containing eugenol, cinnaldehydrum weight ratio in 4-12:1
Between the anti-effect highly significant to depression of composition.
Embodiment
Composition and the composition for a better understanding of the present invention is in the medicine for preparing treatment depression
Purposes, technical scheme and its technique effect is expanded on further with specific embodiment the following, but should not be by following implementation
Example is interpreted as limitation of the present invention.
Embodiment 1
A kind of pharmaceutical composition, forms and is：Eugenol 4g, cinnaldehydrum 1g.
Embodiment 2
A kind of pharmaceutical composition, forms and is：Eugenol 5.5g, cinnaldehydrum 1g.
Embodiment 3
A kind of pharmaceutical composition, forms and is：Eugenol 7g, cinnaldehydrum 1g.
Embodiment 4
A kind of pharmaceutical composition, forms and is：Eugenol 7.5g, cinnaldehydrum 1g.
Embodiment 5
A kind of pharmaceutical composition, forms and is：Eugenol 12g, cinnaldehydrum 1g.
Embodiment 6
A kind of pharmaceutical composition, forms and is：Eugenol 5g, cinnaldehydrum 1g.
Embodiment 7
A kind of pharmaceutical composition, forms and is：Eugenol 6g, cinnaldehydrum 1g.
Embodiment 8
A kind of pharmaceutical composition, forms and is：Eugenol 8g, cinnaldehydrum 1g.
Embodiment 9
A kind of pharmaceutical composition, forms and is：Eugenol 10g, cinnaldehydrum 1g.
Embodiment 10
A kind of pharmaceutical composition, forms and is：Eugenol 11g, cinnaldehydrum 1g.
Embodiment 11
1~10 any pharmaceutical composition of Example, routinely preparation process add auxiliary material tablet is made.
Embodiment 12
1~10 any pharmaceutical composition of Example, routinely preparation process add auxiliary material capsule is made.
Embodiment 13
1~10 any pharmaceutical composition of Example, routinely preparation process add auxiliary material soft capsule is made.
Embodiment 14
1~10 any pharmaceutical composition of Example, routinely preparation process add auxiliary material granule is made.
Embodiment 15
1~12 any pharmaceutical composition of Example, routinely preparation process add auxiliary material powder is made.
The mouse forced swimming of embodiment 16
1. experimental animal
ICR small white mouses, male, 18-20g, cleaning grade, are provided by Shanghai Slac Experimental Animal Co., Ltd., are closed
Lattice card number:SCXK (Shanghai) 2007-0005.
2. medicine
2.1 test specimen
Cinnaldehydrum, 98%, Chengdu Pu Si biotech inc, lot number：PS151228-05.
Eugenol, 98%, Chengdu Pu Si biotech inc, lot number：PS0262-0500.
2.2 positive control drug
Efexor XR (venlafaxine hydrochloride slow-release capsule), 75mg/ grains (in terms of Venlafaxine), Wyeth Pharmaceuticals, lot number：
111004。
3. drug solution preparing
3.1 test specimens and dosage
Cinnaldehydrum group, eugenol group, eugenol:Cinnaldehydrum=4:1 group, eugenol:Cinnaldehydrum=5.5:1 group, eugenol:
Cinnaldehydrum=7:1 group, eugenol:Cinnaldehydrum=7.5:1 group, eugenol:Cinnaldehydrum=12:1 group, using eugenol and/or osmanthus
Skin aldehyde standard items are configured, alone group of dosage is 25mg/kg, and composition group is given according to its different ratio by 0.5%CMC-Na
Pharmaceutical quantities are 20mg/kg.
3.2 positive control drugs and dosage
Venlafaxine hydrochloride slow-release capsule is configured using 0.5%CMC-Na, and dosage is 25mg/kg (with Venlafaxine
Meter).
4. experimental method and result
4.1 animal packet
One day before administration, mouse is put into model equipment 5 minutes, it is small within the 60-160 seconds to choose the dead time
Mouse, 9 groups are randomly divided into by body weight, correspond to blank control group, positive controls, cinnaldehydrum group, eugenol group and 5 proportionings respectively
Composition group, every group of 10 animals.
4.2 test method
Each test group presses the oral gastric infusion of relative medicine, 0.2ml/10g body weight, once a day, successive administration 14 days.End
Mouse forced swimming, swimming continuance time 6min are carried out after secondary administration 1h.Using camera system automatic data collection, record small
Stop the motionless time of swimming in 4min after mouse.
4.3 result
It the results are shown in Table 1.Its mouse oral gives positive controls and 4:1、5.5:1、7:1、7.5:1、12:The cloves of 1 proportioning
The composition of phenol and cinnaldehydrum significantly shorten mouse and swim the slack time after two weeks.Compared with blank control group, fourth
Fragrant phenol and cinnaldehydrum 4:1、12:The P values of 1 composition group are respectively less than 0.05；Positive controls, eugenol and cinnaldehydrum 5.5:1、7:
1、7.5:The P values of 1 composition group are respectively less than 0.01；Cinnaldehydrum group and eugenol group have reduction trend, but compared with blank group
Without significant difference (P>0.05).The dosage of eugenol and cassia bark aldehyde compositions be less than positive controls (Venlafaxine) and
Alone group of eugenol, cinnaldehydrum, 20mg/kg eugenol and cinnaldehydrum 5.5:1、7:1、7.5:The efficacy strength of 1 composition group
25mg/kg alone group of eugenol, cinnaldehydrum are significantly better than, and compared with 25mg/kg Venlafaxine, no statistical difference meaning
Justice (P>0.05).
Data are with mean+SDRepresent, data difference statistics uses one-way analysis of variance
(ANOVA), group difference is with P<0.05th, 0.01 judges.
The composition of table 1 to mouse swimming test influence (n=10,±SD)
The tail suspension test of embodiment 22 is tested
1. experimental animal
ICR small white mouses, male, 18-20g, cleaning grade, are provided by Shanghai Slac Experimental Animal Co., Ltd., are closed
Lattice card number：SCXK (Shanghai) 2007-0005.
2. medicine
2.1 test specimen
Cinnaldehydrum, Chengdu Pu Si biotech inc, lot number：PS151228-05.
Eugenol, Chengdu Pu Si biotech inc, lot number：PS0262-0500.
2.2 positive control drug
Efexor XR (venlafaxine hydrochloride slow-release capsule), 75mg/ grains (in terms of Venlafaxine), Wyeth Pharmaceuticals, lot number：
111004。
3. drug solution preparing
3.1 test specimens and dosage
Cinnaldehydrum group, eugenol group, eugenol:Cinnaldehydrum=4:1 group, eugenol:Cinnaldehydrum=5.5:1 group, eugenol:
Cinnaldehydrum=7:1 group, eugenol:Cinnaldehydrum=7.5:1 group, eugenol:Cinnaldehydrum=12:1 group, using eugenol and/or osmanthus
Skin aldehyde standard items are configured, alone group of dosage is 25mg/kg, and composition group is given according to its different ratio by 0.5%CMC-Na
Pharmaceutical quantities are 20mg/kg.
3.2 positive control drug and dosage
Venlafaxine hydrochloride slow-release capsule is configured using 0.5%CMC-Na, and dosage is 25mg/kg (with Venlafaxine
Meter).
4. experimental method and result
4.1 animal packet
One day before administration, mouse is put into model equipment 5 minutes, it is small in 60-160 seconds to choose the dead time
Mouse, blank control group, positive controls, cinnaldehydrum group, eugenol group and 5 proportioning composition groups are randomly divided into by body weight, often
10 animals of group.
4.2 test method
Each test group presses relative medicine gastric infusion, 0.2ml/10g body weight, once a day, successive administration 14 days.Last is given
Tail suspension test experiment, duration 6min are carried out after medicine 1h.Using camera system automatic data collection, record mouse 6min
The interior actionless time.
4.3 result
It the results are shown in Table 2.Its mouse oral gives positive controls and 4:1、5.5:1、7:1、7.5:1、12:The cloves of 1 proportioning
For the composition of phenol and cinnaldehydrum after two weeks, different degrees of significantly shorten the mouse actionless time.With blank control group
Compare, eugenol and cinnaldehydrum 4:1、12:The difference tool of 1 composition group is statistically significant (P<0.05), positive control
Group, eugenol and cinnaldehydrum 5.5:1、7:1、7.5:The difference of 1 composition group has highly significant meaning (P<0.01)；It is but alone
Group (cinnaldehydrum group and eugenol group) is with blank group more without significant difference (P>0.05).Eugenol and cassia bark aldehyde compositions
Dosage is less than positive controls (Venlafaxine) and alone group of eugenol, cinnaldehydrum, 20mg/kg eugenol and cinnaldehydrum
5.5:1、7:1、7.5:The efficacy strength of 1 composition group is significantly better than alone group of 25mg/kg eugenol, cinnaldehydrum, and with
25mg/kg Venlafaxine is compared, no significant difference (P>0.05).
Data represent that data difference statistics uses one-way analysis of variance with mean+SD (x ± SD)
(ANOVA), group difference is with P<0.05 judges.
Influence that table 2 is tested to tail suspension test (n=10,±SD)
Embodiment 23 stimulates chronic mild unpredictable stress stimulus (CUMS) rat syrup preference and opens the shadow of case motion
Ring
1. animal
Wistar rats, male, 180-200g, by Shanghai, western pul-Bi Kai experimental animals Co., Ltd is provided, and animal is closed
Lattice card number：2008-0016.
2.1 test specimen
Cinnaldehydrum, Chengdu Pu Si biotech inc, lot number：PS151228-05.
Eugenol, Chengdu Pu Si biotech inc, lot number：PS0262-0500.
2.2 positive control drug
Efexor XR (venlafaxine hydrochloride slow-release capsule), 75mg/ grains (in terms of Venlafaxine), Wyeth Pharmaceuticals, lot number：
111004。
3. drug solution preparing
3.1 test specimens and dosage
Cinnaldehydrum group, eugenol group, eugenol:Cinnaldehydrum=4:1 group, eugenol:Cinnaldehydrum=5.5:1 group, eugenol:
Cinnaldehydrum=7:1 group, eugenol:Cinnaldehydrum=7.5:1 group, eugenol:Cinnaldehydrum=12:1 group, using eugenol and/or osmanthus
Skin aldehyde standard items are configured, alone group of dosage is 12.5mg/kg, and composition is given according to its different ratio by 0.5%CMC-Na
Pharmaceutical quantities are 10mg/kg.
3.2 positive control drugs and dosage
Venlafaxine hydrochloride slow-release capsule is configured using 0.5%CMC-Na, and dosage is 12.5mg/kg (with literary daraf(reciprocal of farad)
Pungent meter).
4. experimental method and result
4.1 animal packet
Rat adaptability raise 4 days after, by body weight be randomly divided into blank control group, model control group, positive controls,
Cinnaldehydrum group, eugenol group and 5 proportioning composition groups, every group of 10 animals.
4.2 test method
4.2.1 modeling and administration：After rat adaptability is raised one week, in addition to blank control group, remaining each group starts CUMS
Program.More than the ten kind stress stimulation factors alternately give rat weekly, stimulate the unpredictable stress factor every time of rat lasting
Time and the stimulation that next will be given.The stimulus of experiment is as follows:2 7h flash stimulation；1 17h unclean bedding and padding
150ml water (is poured on bedding and padding) by environment；1 time 3h and 1 time 5h intermittent noise stimulates；(illumination is lasting for 1 night illumination
36h)；1 time 7h and 1 time 22h mouse cages tilt；1 17h group support (5 cages of mouse one), 1 17h strange smell environment raising；1
The secondary strange foreign matter environment of 7h；3 fasting for continuing 19,22 and 24h respectively, the limited supply of forage of 2h is given after each fasting；4
The secondary taboo water for continuing 17,19,20 and 21h respectively, empty bottle 1h is placed after prohibiting water every time.
When rat is since the CUMS, each group is by that should give decoction gastric infusion, once a day, 1ml/100g, successive administration 8
Week is to CUMS EPs (end of program).
4.2.2 experimental method
(1) syrup preference training is carried out to rat before syrup preference experiment modeling.All animals are given in the 24h of beginning
Give 1% sucrose water:1% sucrose water is filled in two bottles, while is placed on the left and right corner of cage.In ensuing 24h
In, while give 1% sucrose water and common drinking water:It is 1% sucrose water in one bottle, is common in another bottle
Drinking water, the left and right corner of cage is still placed on simultaneously.
Before modeling, at the weekend of modeling the 8th, 24h fasting for solids and liquids, syrup preference experiment is carried out:1% sucrose water is given simultaneously
And common drinking water, measure animal amount of drinking of sucrose water and common drinking water in 1h by claiming drinking bottle weight.Calculate
Per mouse syrup preference percentage=[syrup intake/(the syrup intake+total intake of light water) × 100%].
(2) after Open field test last dose, rat is put into the fixed position of the spacious case of self-control, observes and remembers after being applicable 2min
Record the lattice number of creeping (the double hind legs of rat enter next lattice for a lattice of creeping) and standing number (before rat pair of rat in subsequent 4min
Limb is lifted away from bottom and is designated as standing once).
4.3 experimental result
4.3.1 syrup has a preference for experimental result
It the results are shown in Table 3.Compared with blank control animal, to after 8 weeks, model group rats syrup preference degree shows CUMS programs
Write and decline (P<0.01), the pleasant sensation of hints model animal lacks；Compared with model group, positive controls, eugenol:Cassia bark
Aldehyde=5.5:1、7:1、7.5:1 group of statistical significant difference (P<0.01), eugenol:Cinnaldehydrum=4:1、12:1 group of system
Meter learns significant difference (P<0.05), its syrup preference percentage dramatically increases.But cinnaldehydrum group and eugenol group its difference
Without significant (P compared with model group>0.05).The dosage of eugenol and cassia bark aldehyde compositions is less than positive controls
Alone group of (Venlafaxine) and eugenol, cinnaldehydrum, 10mg/kg eugenol and cinnaldehydrum 4:1、5.5:1、7:1、7.5:1、
12:The efficacy strength of 1 composition group is significantly better than alone group of 12.5mg/kg eugenol, cinnaldehydrum, and with 12.5mg/kg's
Venlafaxine is compared, no significant difference (P>0.05).
Table 3 be administered to CUMS rat models syrup preference ratio influence (n=10,±SD)
4.3.2 Open field test result
It the results are shown in Table 4.Compared with blank control animal, CUMS programs are to after 8 weeks, the autonomic activities amount of model group rats
(lattice number of creeping, standing number) is remarkably decreased (P<0.01)；Compared with model group, positive controls, eugenol and cinnaldehydrum are matched somebody with somebody
The statistical significant difference of 5 each groups, animal pattern can be dramatically increased and creeped the effect (P of lattice number and standing number<0.01),
Prompt the low of positive drug and eugenol and cinnaldehydrum compatibility group energy confrontation model independent activity of animals.But cinnaldehydrum group and fourth
Fragrant its difference of phenol group is compared with model group without significant (P>0.05).The dosage of eugenol and cassia bark aldehyde compositions is small
In positive controls (Venlafaxine) and alone group of eugenol, cinnaldehydrum, 10mg/kg eugenol and cinnaldehydrum 5.5:1、7:1、
7.5:The efficacy strength of 1 composition group is significantly better than alone group of 12.5mg/kg eugenol, cinnaldehydrum, and with 12.5mg/kg's
Venlafaxine is compared, no significant difference (P>0.05).
Table 4 be administered to CUMS rat models open case motion influence (n=10,±SD)
5 conclusions
Pass through multinomial in vivo studies, including tail suspension test experiment, mouse swimming test and chronic mild Unpredictability
Stress stimulation (CUMS) is tested, it was demonstrated that not only there is significant antidepressant effect after eugenol and cinnaldehydrum combination, and can also
Reduce the dosage of medicine.The composition effect preferably ratio range containing eugenol, cinnaldehydrum is 4:1-12:1, more
Preferable ratio range is 5.5:1-7.5:1、5.5:1-7:1 or 7:1-7.5:1, most preferably proportioning is 4:1、5.5:1、7:1、
7.5:1 or 12:1.
Claims (10)
1. a kind of pharmaceutical composition, it is characterised in that described pharmaceutical composition includes eugenol and cinnaldehydrum.
2. pharmaceutical composition as claimed in claim 1, it is characterised in that the eugenol, the weight ratio of cinnaldehydrum are (4-
12):1。
3. pharmaceutical composition as claimed in claim 1, it is characterised in that the eugenol, the weight ratio of cinnaldehydrum are (5.5-
7.5):1。
4. pharmaceutical composition as claimed in claim 1, it is characterised in that the eugenol, the weight ratio of cinnaldehydrum are (7-
7.5):1 or (5.5-7):1.
5. pharmaceutical composition as claimed in claim 1, it is characterised in that the eugenol, the weight ratio of cinnaldehydrum are 5.5:
1、7:1 or 7.5:1.
6. the pharmaceutical composition as described in claim any one of 1-5, it is characterised in that the eugenol, the purity of cinnaldehydrum
More than 85%.
7. pharmaceutical composition as claimed in claim 6, it is characterised in that the eugenol, cinnaldehydrum purity 90% with
On.
8. pharmaceutical composition as claimed in claim 7, it is characterised in that the eugenol, cinnaldehydrum purity 95% with
On.
9. the pharmaceutical composition as described in any one of claim 1~8, it is characterised in that described pharmaceutical composition is routinely made
Agent technique is prepared into clinical conventional capsule, soft capsule, tablet, granule, pill, powder or oral liquid.
10. application of the pharmaceutical composition in the medicine for preparing treatment depression described in claim 1~8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610437198.9A CN107510689B (en) | 2016-06-17 | 2016-06-17 | Pharmaceutical composition for treating depression and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610437198.9A CN107510689B (en) | 2016-06-17 | 2016-06-17 | Pharmaceutical composition for treating depression and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107510689A true CN107510689A (en) | 2017-12-26 |
| CN107510689B CN107510689B (en) | 2019-12-17 |
Family
ID=60720639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610437198.9A Active CN107510689B (en) | 2016-06-17 | 2016-06-17 | Pharmaceutical composition for treating depression and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107510689B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108283662A (en) * | 2018-04-23 | 2018-07-17 | 陕西新药技术开发中心 | It is a kind of to treat neurasthenic cassia tree bark oil dripping pill and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810274A (en) * | 2005-01-28 | 2006-08-02 | 郑乐建 | Cassia, its extract cinnamal and their application in preparing medicine for treating depression |
| CN102218091A (en) * | 2010-05-21 | 2011-10-19 | 成都医学院 | Application of cinnamon oil, cinnamyl aldehyde and derivatives of cinnamyl aldehyde in preparation of histamine H3 acceptor antagonist or inverse agonist medicaments |
-
2016
- 2016-06-17 CN CN201610437198.9A patent/CN107510689B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810274A (en) * | 2005-01-28 | 2006-08-02 | 郑乐建 | Cassia, its extract cinnamal and their application in preparing medicine for treating depression |
| CN102218091A (en) * | 2010-05-21 | 2011-10-19 | 成都医学院 | Application of cinnamon oil, cinnamyl aldehyde and derivatives of cinnamyl aldehyde in preparation of histamine H3 acceptor antagonist or inverse agonist medicaments |
Non-Patent Citations (1)
| Title |
|---|
| RUI-SONG PEI ET AL.: "Evaluation of Combined Antibacterial Effects of Eugenol, Cinnamaldehyde,Thymol, and Carvacrol against E. coli with an Improved Method", 《JOURNAL OF FOOD SCIENCE》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108283662A (en) * | 2018-04-23 | 2018-07-17 | 陕西新药技术开发中心 | It is a kind of to treat neurasthenic cassia tree bark oil dripping pill and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107510689B (en) | 2019-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9669043B2 (en) | Synergistic pharmaceutical composition for serotonin reuptake inhibition and process of preparation thereof | |
| WO2019071213A1 (en) | Rapid onset and extended action plant-based and synthetic cannabinoid formulations | |
| KR101735151B1 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN107951869A (en) | Pharmaceutical preparation and its application containing cannabidiol | |
| KR20070085519A (en) | An extractive of piper laetispicum c.dc., its process and its uses | |
| CN106031418A (en) | Composition having physical power fatigue releasing function, and preparation method thereof | |
| CN103002902A (en) | Cosmetic composition containing a cypress essential oil complex as an active ingredient for enhancing memory and improving cognitive dysfunction | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| CN107510689A (en) | A kind of pharmaceutical composition for treating depression and its application | |
| CN104606456A (en) | Health medicine for treating hypertension and hyperlipidemia | |
| CN103251890A (en) | Plant essential oil composition and anxiolytic effect thereof | |
| CN105169290A (en) | Traditional Chinese medicine composition for treating primary trigeminal neuralgia and application thereof | |
| CN102716119A (en) | Novel application of (-)-epigallocatechin gallate in treatment of depression | |
| CN101919924B (en) | Pharmaceutical composition for curing tristimania and preparation method and application thereof | |
| CN108404044B (en) | Compound plant incense essential oil for treating depression | |
| CN1277567C (en) | Medicinal composition for treating nervous system disease and its preparation method | |
| CN101972325A (en) | Medicament composition for treating chick coccidiosis and preparation method thereof | |
| CN105919991B (en) | Application of the euparin in preparation medicament for treatment of depression | |
| CN1792370A (en) | External use prepns. for wind-dispelling, removing-obstruction in channels to relieve pain | |
| CN110279748A (en) | A kind of application of Cortex Magnoliae Officinalis essential oil | |
| RU2497538C2 (en) | AGENT OF HINDU LOTOS SEED (Nelumbo nucifera) EXTRACT POSSESSING ANXIOLYTIC AND ANTIDEPRESSIVE ACTION | |
| TWI377949B (en) | A chinese herb extract for treating dementia and preparation method thereof | |
| CN107693724A (en) | A kind of Chinese medicine for treating rhinitis composition and preparation method thereof | |
| WO2017006351A1 (en) | Herbal dha composition | |
| CN107007590A (en) | Purposes of the epimedium aglucone in prevention or treatment anti-parkinson drug is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |